Switching from Cimzia to Secukinumab: Washout Period
You can start secukinumab immediately after stopping Cimzia without any mandatory waiting period, though monitoring for 3-4 half-lives (approximately 8-12 weeks) may be considered if the patient is clinically stable.
Rationale Based on Guidelines
The 2019 AAD-NPF guidelines provide expert consensus on biologic switching that is relevant here 1. The guidelines state that repeating loading doses should be considered if more than 3-4 half-lives have passed since the previous dose, particularly if the patient is flaring 1. This guidance is meant for restarting the same medication, but it provides insight into the pharmacokinetic considerations for biologic therapy.
Pharmacokinetic Considerations
Certolizumab (Cimzia) Half-Life
- Certolizumab has a half-life of approximately 14 days
- 3-4 half-lives would equal 6-8 weeks for near-complete drug clearance
- However, the FDA label notes that certolizumab is dosed every 2 weeks for maintenance, indicating therapeutic levels are maintained between doses 2
Secukinumab Dosing
- Secukinumab loading regimen: 300 mg at weeks 0,1,2,3, and 4 1
- This intensive loading schedule is designed to achieve rapid therapeutic levels regardless of prior therapy
Clinical Decision Algorithm
For patients with active disease requiring immediate control:
- Start secukinumab immediately after stopping Cimzia
- The weekly loading doses of secukinumab will establish therapeutic levels quickly
- No evidence suggests increased safety risks from overlapping biologic effects
For patients with well-controlled disease:
- May wait 2-4 weeks to assess disease stability off Cimzia
- This allows partial drug clearance while minimizing disease flare risk
- If flaring occurs during this period, initiate secukinumab immediately
For patients with prior serious infections or immunosuppression concerns:
- Consider waiting 4-8 weeks (approximately 3 half-lives of certolizumab)
- Monitor for infection during this interval
- Balance against risk of disease flare
Important Caveats
The guidelines do not specify mandatory washout periods when switching between different biologic classes (TNF-α inhibitor to IL-17 inhibitor) 1. This is clinically significant because:
- Different mechanisms of action: Certolizumab blocks TNF-α while secukinumab blocks IL-17A, reducing concerns about additive immunosuppression
- Real-world practice: Research shows patients successfully transition between biologics without extended washout periods 3, 4
- Disease control priority: Maintaining disease control to prevent morbidity outweighs theoretical concerns about brief overlapping drug effects
Safety Monitoring
Regardless of timing chosen:
- Screen for active infections before starting secukinumab
- Ensure tuberculosis screening is current
- Monitor for signs of infection during the first 12 weeks of secukinumab therapy
- The safety profile of secukinumab is well-established with no specific contraindication to starting after TNF-α inhibitor therapy 1
The absence of specific washout requirements in authoritative guidelines, combined with the different mechanisms of action and the robust loading regimen of secukinumab, supports immediate transition in most clinical scenarios.